Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current.

BACKGROUND Methanesulfonanilide derivatives, selective inhibitors of the rapidly activating component (I(Kr)) of the delayed rectifier potassium current (I(K)), prolong action potential duration (APD) of cardiac muscles with reverse frequency dependence, which limits their clinical use because of proarrhythmia. Vesnarinone, a quinolinone derivative developed as a cardiotonic agent, has complex pharmacological properties, but its clinical efficacy is explained in part by I(K) reduction. Therefore, we investigated the mode of I(K) block by vesnarinone. METHODS AND RESULTS I(K) of the rabbit ventricular myocyte was activated by voltage-clamp steps applied from a holding potential to various depolarizing levels. The development of I(K) block at depolarization (+10 mV) and its recovery process at hyperpolarization (-75 mV) were compared between vesnarinone and E-4031. The I(K) block by vesnarinone (3 micromol/L) developed and recovered monoexponentially, with time constants of 361 ms (n=5) and 1.87 seconds (n=4), respectively. I(K) block by E-4031 (0.3 micromol/L) developed instantaneously, with no recovery from the block at hyperpolarization. The I(K) block by vesnarinone, estimated by I(K) tail after a train of depolarizing pulses (for 30 seconds at 0.2 to 2 Hz), was increased with increasing frequency (twofold at 2 from 0.2 Hz), but that by E-4031 was unchanged. In rabbit papillary muscles, vesnarinone (10 micromol/L) prolonged APD at stimulation frequencies >0.2 Hz, whereas E-4031 (0.3 micromol/L) prolonged that in a reverse frequency-dependent manner. CONCLUSIONS Vesnarinone may prolong the repolarization of human cardiac muscle without reverse frequency dependence, because I(Kr) is expressed in humans as well as in the rabbit. Thus, this drug may be a model for an ideal class III drug without the risk of proarrhythmia.

[1]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[2]  M. Sanguinetti,et al.  Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.

[3]  S. Ogawa,et al.  Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. , 1993, American heart journal.

[4]  D M Roden,et al.  Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. , 1995, Circulation.

[5]  S Nattel,et al.  Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. , 1996, Circulation research.

[6]  R. Bain,et al.  Effects of vesnarinone on morbidity and mortality in patients with heart failure , 1993 .

[7]  T. Colatsky,et al.  Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock. , 1992, Cardiovascular research.

[8]  J. Lynch,et al.  Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents. , 1995, Journal of cardiovascular pharmacology.

[9]  E. Carmeliet Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.

[10]  G M Briggs,et al.  Identification of a specific radioligand for the cardiac rapidly activating delayed rectifier K+ channel. , 1993, Circulation research.

[11]  C. Antzelevitch,et al.  Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. , 1995, Circulation research.

[12]  A. Varró,et al.  Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit, guinea pi , 1993 .

[13]  M. Sanguinetti,et al.  Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.

[14]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[15]  B. Singh,et al.  Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. , 1993, European heart journal.

[16]  H. Inoue,et al.  Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. , 1991, Journal of the American College of Cardiology.

[17]  J. Brachmann,et al.  Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. , 1991, The American journal of cardiology.

[18]  U. Ravens,et al.  Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. , 1994, The Journal of pharmacology and experimental therapeutics.

[19]  A. Camm,et al.  Ambulatory Assessment of the QT Interval in Patients with Hypertrophic Cardiomyopathy: Risk Stratification and Effect of Low Dose Amiodarone , 1994, Pacing and clinical electrophysiology : PACE.

[20]  B F Hoffman,et al.  Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.

[21]  H. Selnick,et al.  Cardiac Electrophysiologic and Inotropic Actions of New and Potent Methanesulfonanilide Class III Antiarrhythmic Agents in Anesthetized Dogs , 1991, Journal of cardiovascular pharmacology.

[22]  W. Stevenson,et al.  Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. , 1990, Circulation.

[23]  H. Mitamura,et al.  Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. , 1996, Journal of the American College of Cardiology.

[24]  K. Kamiya,et al.  Ca2+-calmodulin Mediated Modulation of the Electrical Coupling of Ventricular Myocytes Isolated from Guinea Pig Heart , 1994 .

[25]  D. Noble,et al.  Excitation-contraction coupling and extracellular calcium transients in rabbit atrium: reconstruction of basic cellular mechanisms , 1987, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[26]  S. Roberds,et al.  Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. , 1992, Molecular pharmacology.

[27]  A. Brown,et al.  New Positive Inotropic Agent OPC-8212 Modulates Single Ca2+ Channels in Ventricular Myocytes of Guinea Pig , 1989, Journal of cardiovascular pharmacology.

[28]  G. W. Beeler,et al.  Reconstruction of the action potential of ventricular myocardial fibres , 1977, The Journal of physiology.

[29]  D. Noble,et al.  On the mechanism of isoprenaline‐ and forskolin‐induced depolarization of single guinea‐pig ventricular myocytes. , 1988, The Journal of physiology.

[30]  S Sasayama,et al.  Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. , 1994, The Journal of clinical investigation.

[31]  M. Allessie,et al.  Effects of Heptanol, Class Ic, and Class III Drugs on Reentrant Ventricular Tachycardia: Importance of the Excitable Gap for the Inducibility of Double‐Wave Reentry , 1994, Circulation.

[32]  S Sasayama,et al.  Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. , 1994, Circulation.

[33]  K. Kamiya,et al.  Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. , 1996, Cardiovascular research.

[34]  S Nattel,et al.  Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. , 1996, The American journal of physiology.

[35]  G Duker,et al.  Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. , 1993, Cardiovascular research.

[36]  S. Sasayama,et al.  Sustained inotropic effects of a new cardiotonic agent. OPC‐8212 in patients with chronic heart failure , 1989, Clinical cardiology.

[37]  P. Sager,et al.  Frequency-dependent electrophysiologic effects of amiodarone in humans. , 1993, Circulation.

[38]  M. Sanguinetti,et al.  Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. , 1991, Circulation research.

[39]  A. Matsumori,et al.  Therapeutic Effect of Anti‐Tumor Necrosis Factor‐α Antibody on the Murine Model of Viral Myocarditis Induced by Encephalomyocarditis Virus , 1994, Circulation.

[40]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[41]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[42]  B. Singh,et al.  Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: block of delayed outward potassium current. , 1992, The Journal of pharmacology and experimental therapeutics.

[43]  I Kodama,et al.  Effects of long-term oral administration of amiodarone on the ventricular repolarization of rabbit hearts. , 1996, Japanese circulation journal.

[44]  A. V. van Ginneken,et al.  Single delayed rectifier channels in the membrane of rabbit ventricular myocytes. , 1993, Circulation research.

[45]  D DiFrancesco,et al.  A model of cardiac electrical activity incorporating ionic pumps and concentration changes. , 1985, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[46]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[47]  E. Carmeliet Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. , 1993, Circulation research.

[48]  L. Carlsson,et al.  Prolonged Action Potential Duration and Positive Inotropy Induced by the Novel Class III Antiarrhythmic Agent H 234/09 (Almokalant) in Isolated Human Ventricular Muscle , 1991, Journal of cardiovascular pharmacology.

[49]  K. Kamiya,et al.  Effects of long‐term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle , 1992, British journal of pharmacology.

[50]  N. Taira,et al.  Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. , 1987, The Journal of pharmacology and experimental therapeutics.

[51]  A. Varró,et al.  Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol. , 1989, European journal of pharmacology.